TrialJournal of neurology, neurosurgery, and psychiatry2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.
Fatemeh Khani-Habibabadi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.